Tissue resident lymphocytes are present within many organs, and are presumably transferred at transplantation, but their impact on host immunity is unclear. Here, we examine whether transferred donor natural regulatory CD4 T cells (nT-regs) inhibit host alloimmunity and prolong allograft survival. Transfer of donor-strain lympho- 
| INTRODUC TI ON
Although still considered a novel technology, ex vivo perfusion of recovered organs from deceased donors is likely to become widely adopted in the near future. 1, 2 Ex vivo perfusion offers the potential to assess the viability of organs before transplantation, and to extend the acceptable period between recovery and implantation. It may also enable targeting of the isolated organs with specific therapies aimed at prolonging allograft survival. 3 One particular focus of such strategies is likely to be donor-derived T cell populations (naïve or memory) that are resident within the graft. 4, 5 We have recently reported that passenger T cells are present within human donor organs recovered for transplantation and, using murine transplant models, have demonstrated that donor T effector cells can augment host alloimmune responses directed against the allograft. 6 Thus, although seemingly counterintuitive, these passenger lymphocytes contribute to rejection of the organ. Here, we examine whether donor-derived natural regulatory CD4 T cells (nTregs) can, conversely, prolong allograft survival.
| MATERIAL S AND ME THODS

| Identification of circulating donor CD4 T lymphocytes in human lung transplant recipients
Following adult deceased-donor lung or heart plus lung transplantation, blood from consenting recipients was sampled at predetermined time points (initially weekly for the first 2 months after transplantation, and monthly/bimonthly thereafter) and donor CD4 and with the relevant MHC class I HLA-specific biotinylated antibody that were selected to bind exclusively to donor (but not recipient) HLA class I MHC alloantigen (see Table S1 ; kindly gifted 
| Characterization of lymphocyte subsets released during ex vivo normothermic perfusion
Kidneys underwent 1 hour of normothermic machine perfu- 
| Heterotopic heart transplantation
Vascularized cardiac allografts were transplanted intra-abdominally as described previously. 9, 10 Heart graft survival was monitored by daily abdominal palpation, with rejection defined as cessation of a detectable beat. Grafts were excised at predetermined time points after transplantation and stored at −80°C or fixed in 10% buffered formalin. In certain experiments, recipient B6 mice were depleted of CD4 T-regs by treatment with 0.5 mg of anti-CD25 mAb (PC-61, Bio X Cell, West Lebanon, NH), i.p., on day -1 followed by 0.25 mg, i.p., on days 1, 3, 5, and 7, in relation to bm12 heart graft transplantation.
Donor T-reg depletion was achieved by administering 0.5 mg of anti-CD25 mAb (PC-61), i.p., on days -6 and -2 before recovery of heart allograft. Pilot experiments confirmed that this treatment resulted in depletion of typically 85%-90% of FoxP3 +ve splenic CD4 T cells. 
| Adoptive transfer of donor/recipient-derived nT-regs
| Histopathology
Cardiac allograft vasculopathy was assessed on elastin van Giesonstained paraffin sections by morphometric analysis as described previously. 11 Luminal stenosis [percentage cross-sectional area luminal stenosis = (area within internal elastic lamina -area of lumen)/area within internal elastic lamina × 100]. All elastin-positive vessels in each section were evaluated, with approximately 10 vessels/heart analyzed.
| Statistics
Data were presented as mean ± standard deviation (SD) where appropriate. Mann-Whitney tests were used for analysis of nonparametric data. Two-way analysis of variance (ANOVA) was employed for comparison of antinuclear and anti-vimentin autoantibody responses. Graft survival was depicted using Kaplan-Meier analysis and groups compared by log-rank (Mantel-Cox) testing. Analysis was conducted using GraphPad 4 (GraphPad Software, San Diego, CA).
Values of P < .05 were considered significant.
| RE SULTS
| Different CD4 T cell lineages are released from human allografts
Having previously demonstrated the presence of CD4 T effector cells within human organs recovered for transplantation, 6 ,12 we sought to determine whether donor CD4 T cells, and specifically, donor T-regs, could potentially also be released into the recipient's circulation following transplantation. Human lung transplant recipients (n = 21) were therefore followed for the first year following transplantation, and the presence of circulating donor-derived CD4 T cells determined by surface expression of mismatched HLA donor antigen ( Figure S1 ). As shown in Figure 1 , donor-derived CD4
T cells were detectable immediately following transplantation in all patients, representing between 0.06% and 6% of the total CD4 T cell population detectable in the recipient (mean chimerism at 1 week;
1.54 ± 1.41%). Numbers of cells recovered were too small to defi- The release of donor T-regs was then assessed by analysis of leukocyte filters recovered from human kidneys that had been obtained using standard recovery techniques, but then perfused normothermically ex vivo using leukocyte-depleted blood. 
| T-reg depletion results in augmented humoral immunity and accelerated allograft rejection
The influence of donor and recipient T-regs on allograft outcomes was then examined using an MHC class II-mismatched murine model of chronic heart allograft rejection. Our previous work has highlighted that chronic allograft vasculopathy (CAV) in this model is associated with the development of effector autoantibody responses that are triggered by graft-versus-host recognition of MHC class II on host B cells by passenger donor CD4 T lymphocytes. 6, 12, 13 In comparison to unmodified WT C57BL/6 recipients, depletion of the T-reg population by administration of anti-CD25 mAb to C57BL/6 mice at, and following, transplantation with bm12 (B6(C)-H2-Ab1bm12/KhEgJ) heart allografts resulted in much more rapid heart graft rejection, and was associated with markedly augmented host autoantibody responses (Figure 2A,B) . This accelerated rejection was nevertheless dependent on adoptive transfer of donor CD4 T cells, because heart Figure 2A ). This suggests that the T-regs were principally influencing the donor T cell/host B cell axis.
| Donor-derived T-regs prolong allograft survival more effectively than recipient T-regs
In the preceding experiments, anti-CD25 treatment of the recipient was continued after transplantation, raising the possibility that ) bm12 donor mice were transplanted into unmodified WT C57BL/6 (B6) or T-reg-depleted recipients and effector autoantibody responses (A), allograft survival (B), and allograft vasculopathy at explant on day 100 (C) was assessed (allograft vasculopathy for T-reg-depleted recipients of WT bm12 heart allografts were not analyzed because of rapid graft destruction). T-reg depletion results in augmented autoantibody responses (P = .04, KruskalWallis test) and rapid allograft rejection (*P < .0001, log-rank test), but this impact is dependent on transfer of passenger donor T cells. 
| D ISCUSS I ON
Our results demonstrate that following solid organ transplantation, donor-derived CD4 T cells are released into the recipient circulation, and, at least following lung transplantation, may persist for some time. Within a larger population of conventional CD4 T effector cells, smaller numbers of regulatory T cells can be identified, and our murine studies confirm that these can inhibit host adaptive immune responses. These findings may hold particular pertinence to ex vivo organ perfusion strategies currently being developed; they highlight that rather than blanket depletion, preservation of select passenger lymphocyte subsets within the allograft may be beneficial.
It is perhaps surprising that donor-derived nT-regs were more effective than recipient-derived nT-regs at blocking host humoral responses. Although the precise target epitopes remain ill-defined, 16, 17 nT-regs are thought to recognize specific, self-restricted peptide epitopes (typically autoantigens 18 ). Donor-derived nT-regs therefore presumably recognize intact host MHC class II complexes on recipient cells via the direct pathway, 19 and in which case, do so with a much greater precursor frequency than for a self-restricted response, with approximately 5% of the clonal repertoire responding. 20 We have recently demonstrated that this enables naïve donor T cells to provide promiscuous, "peptide-degenerate" help to all host B cells, with plasma cell differentiation dictated by simultaneous B cell receptor ligation. 6, 21 By extension, recognition of MHC class II alloantigen on host B cells by passenger T-regs within the allograft is likely to provide broad inhibition of host humoral immunity. Whether this inhibition is the result of direct killing of the B cell by the Treg, [22] [23] [24] [25] or delivery of inhibitory signals to the B cell, 26, 27 or blockade of delivery of essential help from CD4 T effector cells is as yet unknown and is the subject of ongoing investigation in our laboratory. Of particular interest, our recent work has highlighted a critical role for germinal center autoantibody 28 and alloantibody 29, 30 reactions in the progression of allograft vasculopathy, and our ongoing II. 32 In this regard, it is notable that heart allografts that contain memory CD4 T cells specific for host MHC class II (by priming the donor with recipient alloantigen 6 weeks prior to heart donation) are rejected much more rapidly than hearts from unmodified donors, with greatly augmented autoantibody responses. 6, 28 Such a use of third-party T-regs to block host humoral alloimmunity would be distinctly different from proposed strategies that differentiate/expand T-regs with self-restricted specificity for alloantigen from the individual's endogenous T cell population, 25, 33 and may offer a particular advantage. T cell help for alloantibody production can only be provided by host CD4 T cells with indirect allospecificity. [34] [35] [36] Thus, for maximum effectiveness, recipient-derived T-regs would need to recognize the relevant allopeptide epitope presented by host MHC class II. Prediction of these peptides is, however, challenging, not least because the repertoire of presented allopeptide peptides may change with time. 37 In contrast, 
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